Abstract:Self-assembly of tau into neurotoxic oligomers and fibrils, and cell-to-cell spreading of these pathological tau species are critical processes underlying the pathogenesis of Alzheimer's disease (AD) and other tauopathies. Modulating the self-assembly process and inhibiting formation and spreading of such toxic species are promising strategies for therapy development. A challenge in investigating tau self-assembly in vitro is that unlike most amyloidogenic proteins, tau does not aggregate in the absence of posttranslational modifications or aggregation inducers. The most common induction method is addition of polyanions, such as heparin, yet this artificial system is not an adequate representation of tau self-assembly in vivo, which is driven by aberrant phosphorylation and other PTMs, potentially leading to in-vitro data that do not represent adequately the behavior of tau and its interaction with modulators in vivo. To tackle these challenges, we compared heparin- induce tau and in-vitro phosphorylated tau aggregation and seeding, and their modulation by a “molecular tweezer”. 2N4R tau was either induced to aggregate by heparin or phosphorylated in-vitro either by ERK2 or by whole rat-brain extract. Aggregation was monitored by thioflavin T fluorescence and electron microscopy. Seeding activity was measured in a FRET-based biosensor cell line. Inhibition of these activities by the molecular tweezer, CLR01, was assessed using the same techniques. Heparin-induced tau behaves differently from in-vitro phosphorylated tau. The aggregation rates of the different forms are distinct as is the intracellular localization of the induced aggregates, which resembles brain-derived tau strains. CLR01 inhibits aggregation and seeding of in-vitro-phosphorylated tau dose-dependently, whereas heparin induction interferes with the interaction between CLR01 and tau. In-vitro phosphorylated tau represents a closer proxy of disease-associated hyperphosphorylated tau than heparin-induced tau and a better system for testing assembly modulators. Using heparin-induced tau aggregation is convenient, but may yield misleading results.

Bioinspired Self-assembly Nanochaperone Inhibits Tau-Derived PHF6 Peptide Aggregation in Alzheimer’s Disease

Engineering a pathological tau-targeted nanochaperone for selective and synergetic inhibition of tau pathology in Alzheimer's Disease

Novel Cathepsin D Inhibitors Block the Formation of Hyperphosphorylated Tau Fragments in Hippocampus

Self-assembly Hollow Manganese Prussian White Nanocapsules Attenuate Tau-related Neuropathology and Cognitive Decline.

A Tauopathy-Homing and Autophagy-Activating Nanoassembly for Specific Clearance of Pathogenic Tau in Alzheimer's Disease.

Deciphering the Inhibitory Mechanism of Naphthoquinone-Dopamine on the Aggregation of Tau Core Fragments PHF6* and PHF6

Harnessing Nanochaperone-Mediated Autophagy for Selective Clearance of Pathogenic Tau Protein in Alzheimer's Disease

Synthetic chaperone based on Hsp90-Tau interaction inhibits pathological Tau aggregation and rescues physiological Tau-Microtubule interaction

Disruption of PHF6 Peptide Aggregation from Tau Protein: Mechanisms of Palmatine Chloride in Preventing Early PHF6 Aggregation

D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease

Inhibition of Aβ Aggregation and Tau Phosphorylation with Functionalized Biomimetic Nanoparticles for Synergic Alzheimer's Disease Therapy

A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies

How short peptides can disassemble ultra-stable tau fibrils extracted from Alzheimer’s disease brain by a strain-relief mechanism

Specific Knockdown of Endogenous Tau Protein by Peptide-Directed Ubiquitin-Proteasome Degradation.

A novel D-amino acid peptide with therapeutic potential (ISAD1) inhibits aggregation of neurotoxic disease-relevant mutant Tau and prevents Tau toxicity in vitro

Synthesis and conformational properties of phosphopeptides related to the human tau protein.

Selective degradation of hyperphosphorylated tau by proteolysis-targeting chimeras ameliorates cognitive function in Alzheimer's disease model mice

F2-06-01: MAJOR DIFFERENCES BETWEEN THE SELF-ASSEMBLY, SEEDING BEHAVIOR, AND INTERACTION WITH MODULATORS OF HEPARIN-INDUCED VERSUS IN-VITRO PHOSPHORYLATED TAU

Tau Protein Associated Inhibitors in Alzheimer Disease

The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model

ChemInform Abstract: Tau Protein Associated Inhibitors in Alzheimer Disease